Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03939065 · ClinicalTrials.gov registry record · NA
Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management
A NA study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT03939065: Clinical Trial NA study, sponsored by University of Colorado, Denver.
NCT03939065 is a NA study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03939065, a NA study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This research proposes a pilot study using the combination of continuous glucose monitor (CGM) and insulin pump therapy, also known as sensor augmented pump (SAP) therapy, for cystic fibrosis related diabetes (CFRD) management in the inpatient setting, with the aim of improving glycemic control.
Primary Outcome
Differences in percent time \>140 mg/dl on CGM between groups
Interventions
- DEVICE Sensor Augmented Pump Therapy
- DEVICE Standard of Care with CGM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-06-12 |
| Est. Completion | 2022-06-30 |
| Phase | NA |
Why NCT03939065 stopped before completion
NCT03939065 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Sensor Augmented Pump Therapy is the first listed.
NCT03939065 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03939065 about?
NCT03939065 is a clinical study titled "Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management". This research proposes a pilot study using the combination of continuous glucose monitor (CGM) and insulin pump therapy, also known as sensor augmented pump (SAP) therapy, for cystic fibrosis related diabetes (CFRD) management in the inpatient setting, with the aim of improving glycemic control.
What is the current status of trial NCT03939065?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2020-06-12. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT03939065?
The interventions under investigation include: Sensor Augmented Pump Therapy (DEVICE), Standard of Care with CGM (DEVICE).
Who is sponsoring clinical trial NCT03939065?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03939065's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI